<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200513047418N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-06-02</date_registration>
      <primary_sponsor>Yazd University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of the effect of ketamine and bupivacaine combination on shoulder pain after gallbladder surgery by laparoscopy</public_title>
      <acronym></acronym>
      <scientific_title>Investigate the Effect of Interaperitoneal ketamin plus bupivacaine administration  for pain relief laparascopic cholecystectomy and comparison with bupivacaine alon</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-07-01</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/48136</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Other design features: no have, Randomization description: For simple randomization, numbers 1-30 were considered for group one intervention, numbers 31-60 for group tow intervention, and numbers 61-90 for group three intervention were considered. Using computer software, sequences of random numbers were creat in the numerical range 1-90. The numbers were recorded and assigned to one of the three groups based on the numerical range defined by each group. hen a card was prepared according to the number of samples and on them was written one of the numbers 1,2,3 that represented the type of group. Based on the created sequence, the card for each group was placed in similar envelopes and arranged in a box. In order to maintain a random sequence, numbering was performed on the outer surface of the envelopes, respectively. fter obtaining the patient's consent, one of the letters was opened and the patient's group was identified based on the card number. The random allocation was hidden by the envelope, Blinding description: An evaluator of study variables is the ward nurse who was unaware of the type of study and the subject of the study as well as the type of medication the patients received. Patients were unaware of their group and the medication they should receive And they were told that they were in one of the study groups.</study_design>
      <phase>3</phase>
      <hc_freetext>Shoulder pain after laparoscopic surgery.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In this group, 10 cc of bupivacaine 0.5% is combined with 0.5 mg / kg of ketamine, and with a normal saline of 0.9%, the volume of the drug reaches 20 cc.The compound is injected into the peritoneum at the end of the surgery and after the gallbladder is removed. Intervention 2: Intervention group: In the second group, 10 cc of bupivacaine 0.5% with 10 cc of normal saline 0.9%, reaches a volume of 20 cc, and at the end of surgery and after removing the gallbladder, is injected into the peritoneum at the site of surgery. Intervention 3: Control group: 20 cc of normal saline is injected into the peritoneum as  a placebo at the end of surgery and after removal of the gallbladder.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All potential data can be shared after people have not been identified.

When:
Start the course after publishing the results

To whom:
For researchers at academic and scientific institutions

Conditions:
The applicant's academic resume is required.

Where to obtain:
They can contact us by email: p.ziaiei@ssu.ac.ir

How to obtain:
The person receives the data by sending his / her scientific resume for a maximum of 3 months.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Parvin Ziaiei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>NO. 30 , Saadi Lane., Saadi Cross., Eastern Hasht Behesht Ave.,</address>
        <city>Esfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>81579-55981</zip>
        <telephone>+98 31 3265 3741</telephone>
        <email>p.ziaiei@ssu.ac.ir</email>
        <affiliation>Yazd University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Saeed Kargar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Sadoughi Hospital., Ibn Sina St., Shahid Ghandi Blvd</address>
        <city>Yazd</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8916886938</zip>
        <telephone>+98 35 3822 4000</telephone>
        <email>saeedkargar@yahoo.com</email>
        <affiliation>Yazd University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>elective laparascopic cholecystectomy
age 18 -65 year
weight 55-100 kg
The duration of surgery is less than two hours.
No neurovascular disease, coagulation disorders, cardiovascular disease • No history of ketamine and bupivacaine allergy
No history of abdominal surgery</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>use of  alcohol, painkillers and anti-inflammatory and non-steroidal anti-inflammatory drugs
Having chronic pain unrelated to gallbladder disease
Dissatisfaction of the patient to continue participating in this study
he need for laparotomy during laparoscopy
having acute cholecystitis
People who could not understand VAS.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>R52</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Pain, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In this group, 10 cc of bupivacaine 0.5% is combined with 0.5 mg / kg of ketamine, and with a normal saline of 0.9%, the volume of the drug reaches 20 cc.The compound is injected into the peritoneum at the end of the surgery and after the gallbladder is removed.</i_keyword>
      <i_keyword>Intervention group: In the second group, 10 cc of bupivacaine 0.5% with 10 cc of normal saline 0.9%, reaches a volume of 20 cc, and at the end of surgery and after removing the gallbladder, is injected into the peritoneum at the site of surgery.</i_keyword>
      <i_keyword>Control group: 20 cc of normal saline is injected into the peritoneum as  a placebo at the end of surgery and after removal of the gallbladder.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The severity of shoulder pain after laparoscopic surgery on (Visual Analogue Scale). Timepoint: Two, four, six, eight hours after surgery. Method of measurement: Visual Analogue Scale(VAS).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Hypotension, pressure drop above 20% initial value. Timepoint: An hour before surgery and two, four, six, eight hours after laparoscopic cholecystectomy. Method of measurement: By a sphygmomanometer.</sec_outcome>
      <sec_outcome>Number of heartbeats. Timepoint: An hour before surgery and in 2-4-6-8 hours after surgery. Method of measurement: By counting the number of pulses per minute that is recorded in the checklist.</sec_outcome>
      <sec_outcome>Dosage of analgesics. Timepoint: 8 hours after surgery. Method of measurement: Using a syringe, it is registered in the checklist in milligrams.</sec_outcome>
      <sec_outcome>The first time analgesics are needed. Timepoint: 8 hours after surgery. Method of measurement: It is registered in the checklist and based on the minute.</sec_outcome>
      <sec_outcome>Nausea and vomiting. Timepoint: 2-4-6-8 hours after surgery. Method of measurement: View and ask .By options has and does not have in the checklist.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Yazd University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-07-29</approval_date>
        <contact_name>Ethics Committee of the Faculty of Health, Shahid Sadoughi University of Medical Sciences, Yazd</contact_name>
        <contact_address>Alam Square,. Shahid Sadoughi University of Medical Sciences Campus,. Yazd - Faculty of Health. Yazd Yazd Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
